Publisher
Springer Science and Business Media LLC
Reference285 articles.
1. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D’Silva NJ, Kapila YL (2011) Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 117:1670–1678
2. Alhazzazi TY, Kamarajan P, Xu Y, Ai T, Chen L, Verdin E, Kapila YL (2016) A novel sirtuin-3 inhibitor, LC-0296, inhibits cell survival and proliferation, and promotes apoptosis of head and neck cancer cells. Anticancer Res 36:49–60
3. Alleyn M, Breitzig M, Lockey R, Kolliputi N (2018) The dawn of succinylation: a posttranslational modification. Am J Physiol Cell Physiol 314:C228–c232
4. Bae NS, Swanson MJ, Vassilev A, Howard BH (2004) Human histone deacetylase SIRT2 interacts with the homeobox transcription factor HOXA10. J Biochem 135:695–700
5. Bajrami I, Walker C, Krastev DB, Weekes D, Song F, Wicks AJ (2021) Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. Commun Biol 4:1270